Document:

<PAGE>

                         CALYPTE BIOMEDICAL CORPORATION

                            1995 DIRECTOR OPTION PLAN

                           AMENDED AS OF JUNE 13, 2000

         1.       Purposes of the Plan.

         The purposes of this Director Option Plan are to attract and retain the
best available personnel for service as Outside Directors (as defined herein) of
the Company, to provide additional incentive to the Outside Directors of the
Company to serve as Directors, and to encourage their continued service on the
Board.

         All options granted hereunder shall be "non-statutory stock options."

         2.       Definitions.

         As used herein, the following definitions shall apply:

                  (a)      "Board" means the Board of Directors of the Company.

                  (b)      "Code" means the Internal Revenue Code of 1986, as
amended.

                  (c)      "Common Stock" means the Common Stock of the Company.

                  (d)      "Company" means Calypte Biomedical Corporation, a
Delaware corporation.

                  (e)      "Continuous Status as a Director" means the absence
of any interruption or termination of service as a Director.

                  (f)      "Director" means a member of the Board.

                  (g)      "Employee" means any person, including officers and
Directors, employed by the Company or any Parent or Subsidiary of the Company.
The payment of a Director's fee by the Company shall not be sufficient in and of
itself to constitute "employment" by the Company. Any person who is not employed
by the Company but who is engaged by the Company to render services as a
consultant is not considered an Employee under this Plan.

                  (h) "Exchange Act" means the Securities Exchange Act of 1934,
as amended.

                  (i)      "Fair Market Value" means, as of any date, the value
of Common Stock determined as follows:

                           (i)      If the Common Stock is listed on any
established stock exchange or a national market system, including without
limitation the National Market System of the National Association of Securities
Dealers, Inc. Automated Quotation ("NASDAQ") System, the

<PAGE>

Fair Market Value of a Share of Common Stock shall be the closing sales price
for such stock (or the closing bid, if no sales were reported) as quoted on such
system or exchange (or the exchange with the greatest volume of trading in
Common Stock) on the date of grant, as reported in The Wall Street Journal or
such other source as the Board deems reliable;

                           (ii)     If the Common Stock is quoted on the NASDAQ
System (but not on the National Market System thereof) or regularly quoted by a
recognized securities dealer but selling prices are not reported, the Fair
Market Value of a Share of Common Stock shall be the mean between the bid and
asked prices for the Common Stock on the last market trading day prior to the
day of determination, as reported in The Wall Street Journal or such other
source as the Board deems reliable, or;

                           (iii)    In the absence of an established market for
the Common Stock, the Fair Market Value thereof shall be determined in good
faith by the Board.

                  (j)      "Immediate Family Members" means the spouse, children
or grandchildren of the Optionee.

                  (k)      "Option" means a stock option granted pursuant to the
Plan.

                  (l)      "Optioned Stock" means the Common Stock subject to an
Option.

                  (m)      "Optionee" means an Outside Director who receives an
Option.

                  (n)      "Outside Director" means a Director who is not an
Employee.

                  (o)      "Parent" means a "parent corporation", whether now or
hereafter existing, as defined in Section 424(e) of the Code.

                  (p)      "Plan" means this Director Option Plan.

                  (q)      "Share" means a share of the Common Stock, as
adjusted in accordance with Section 10 of the Plan.

                  (r)      "Subsidiary" means a "subsidiary corporation",
whether now or hereafter existing, as defined in Section 424(f) of the Internal
Revenue Code of 1986.

                  (s)      "Term of Office" means the period of time commencing
with the date of any annual meeting of the Company's stockholders at which
Directors are elected and the date of the next subsequent stockholders' meeting
at which Directors are elected.

         3.       Stock Subject to the Plan.

         Subject to the provisions of Section 10 of the Plan, the maximum
aggregate number of Shares which may be optioned and sold under the Plan is
850,000 Shares (the "Pool") of Common Stock. The Shares may be authorized but
unissued, or reacquired Common Stock.

                                       2
<PAGE>

         If an Option should expire or become unexercisable for any reason
without having been exercised in full, the unpurchased Shares which were subject
thereto shall, unless the Plan shall have been terminated, become available for
future grant under the Plan.

         4.       Administration of and Grants of Options under the Plan.

                  (a)      Procedure for Grants. The provisions set forth in
this Section 4(a) shall not be amended more than once every six months, other
than to comport with changes in the Code, the Employee Retirement Income
Security Act of 1974, as amended, or the rules thereunder. All grants of Options
to Outside Directors under this Plan shall be discretionary provided such grants
are made strictly in accordance with the following provisions:

                           (i)      The Board shall have discretionary authority
to determine the number of shares of Common Stock to be granted to Outside
Directors on the date on which each person first becomes a Director.

                           (ii)     The Board shall have discretionary authority
to determine the number of Options to be granted to each re-elected Director.

                  (b)      Option Grants. Each Option granted hereunder will
include the following terms:

                           (i)      The term of the Option will be ten (10)
years.

                           (ii)     The Option will be exercisable at any time
during the term of the Option to the extent that the Option has become vested,
regardless of whether the Optionee has terminated service as a member of the
Board, provided however that if an Optionee is removed from the Board, the
Option will terminate if it is not exercised within 90 days of the date of such
removal, but in no event later than the expiration of the ten (10) year term of
the Option.

                           (iii)    The exercise price per Share will be 100% of
the fair market value per Share on the date of grant of the Option.

                           (iv)     During the period that an Optionee serves as
a Director, the Option will vest monthly at a rate of 8.33% per month over the
twelve (12) month period commencing with the date of election of the Optionee as
Director. The Option will vest at such rate on the first day of each month
subsequent to such election, provided that such Option will become vested and
fully exercisable on the date of the next annual meeting of stockholders if such
meeting occurs less than twelve months after the date of the grant.

                           (v)      In the event that any Option granted under
the Plan would cause the number of Shares subject to outstanding Options plus
the number of Shares previously purchased under Options to exceed the Pool, then
the remaining Shares available for Option grant shall be granted under Options
to the Outside Directors on a pro rata basis. No further grants shall be made
until such time, if any, as additional Shares become available for grant under
the Plan through action of the Board to increase the number of Shares which may
be issued

                                       3
<PAGE>

under the Plan; provided, further that such Options shall not be exercisable
until such time, if any, as the increased approved by the Board is approved by
the shareholders.

         5.       Eligibility.

         Options may be granted only to Outside Directors; provided, however,
that if an Outside Director is nominated to the Company's Board pursuant to an
agreement between the Company and another person or entity, options granted
under the Plan may be granted to such other person(s) or entity or an affiliate
of same. All Options shall be granted in accordance with the terms set forth in
Section 4 hereof. An Outside Director who has been granted an Option may, if he
is otherwise eligible, be granted an additional Option or Options in accordance
with such provisions.

         The Plan shall not confer upon any Optionee any right with respect to
continuation of service as a Director or nomination to serve as a Director, nor
shall it interfere in any way with any rights which the Director or the Company
may have to terminate his or her directorship at any time.

         6.       Term of Plan.

         The Plan shall become effective upon the earlier to occur of its
adoption by the Board or its approval by the shareholders of the Company as
described in Section 16 of the Plan. It shall continue in effect for a term of
ten (10) years unless sooner terminated under Section 11 of the Plan.

         7.       Form of Consideration.

         The consideration to be paid for the Shares to be issued upon exercise
of an Option, including the method of payment, shall consist of (i) cash, (ii)
check, (iii) delivery of a properly executed exercise notice together with such
other documentation as the Company and the broker, if applicable, shall require
to effect an exercise of the Option and delivery to the Company of the sale or
loan proceeds required to pay the exercise price, or (iv) any combination of the
foregoing methods of payment.

         8.       Exercise of Option.

                  (a) Procedure for Exercise; Rights as a Shareholder. Any
Option granted hereunder shall be exercisable at such times as are set forth in
Section 4 hereof, provided, however, that no Options shall be exercisable until
shareholder approval of the Plan in accordance with Section 16 hereof has been
obtained. An Option may not be exercised for a fraction of a Share.

         An Option shall be deemed to be exercised when written notice of such
exercise has been given to the Company in accordance with the terms of the
Option by the person entitled to exercise the Option and full payment for the
Shares with respect to which the Option is exercised has been received by the
Company. Full payment may consist of any consideration and method

                                       4
<PAGE>

of payment allowable under Section 7 of the Plan. Until the issuance (as
evidenced by the appropriate entry on the books of the Company or of a duly
authorized transfer agent of the Company) of the stock certificate evidencing
such Shares, no right to vote or receive dividends or any other rights as a
shareholder shall exist with respect to the Optioned Stock, notwithstanding the
exercise of the Option. A share certificate for the number of Shares so acquired
shall be issued to the Optionee as soon as practicable after exercise of the
Option. No adjustment will be made for a dividend or other right for which the
record date is prior to the date the stock certificate is issued, except as
provided in Section 10 of the Plan.

         Exercise of an Option in any manner shall result in a decrease in the
number of Shares which thereafter may be available, both for purposes of the
Plan and for sale under the Option, by the number of Shares as to which the
Option is exercised.

                  (b)      Rule 16b-3. Options granted to Outside Directors must
comply with the applicable provisions of Rule 16b-3 promulgated under the
Exchange Act or any successor thereto and shall contain such additional
conditions or restrictions as may be required thereunder to qualify for the
maximum exemption from Section 16 of the Exchange Act with respect to Plan
transactions.

                  (c)      Termination of Continuous Status as a Director. In
the event an Optionee's Continuous Status as a Director terminates, the
Optionee's vesting in his or her Options granted under this Plan will cease as
of the date of such termination.

                  (d)      Death of Optionee. In the event of an Optionee's
death, the Optionee's estate or a person who acquired the right to exercise the
Option by bequest or inheritance may exercise the Option to the extent that the
Optionee was entitled to exercise it at the date of death (but in no event later
than the expiration of its ten (10) year term). To the extent that the Optionee
was not entitled to exercise an Option at the date of death, and to the extent
that the Optionee's estate or a person who acquired the right to exercise such
Option does not exercise such Option (to the extent otherwise so entitled)
within the time specified herein, the Option shall terminate.

         9.       Assignment or Transfer.

                  (a)      All or any portion of any Option may be transferred
by an Optionee to (i) the Immediate Family Members of the Optionee, (ii) a
partnership in which such Immediate Family Members are the only partners, or
(iii) a trust or trusts for the exclusive benefit of such Immediate Family
Members, provided that (x) there may be no consideration for such transfer, (y)
the agreement pursuant to which such Options are transferred must be in a form
consistent with the Plan, and must expressly provide for transferability in a
manner consistent with this Section 9, and (z) subsequent transfers of
transferred Options shall be prohibited except those by will or the laws of
descent and distribution. Following transfer, any such Options shall continue to
be subject to the same terms and conditions as were applicable immediately prior
to transfer. The effect of termination of the Optionee's service on the Board of
Directors shall continue to be applied with respect to the original Optionee,
following which the Options shall be exercisable by the transferee only to the
extent, and for the periods specified in the Plan on the occurrence of

                                       5
<PAGE>

such termination. Neither the Company nor the administrator of the Plan shall
have any obligation to provide the transferee with notice of termination of an
Optionee.

                  (b)      Options shall be transferable only in accordance with
Section 9(a) or by will or the laws of descent and distribution.

         10.      Adjustments Upon Changes in Capitalization, Dissolution,
                  Merger, Asset Sale or Change of Control.

                  (a)      Changes in Capitalization. Subject to any required
action by the shareholders of the Company, the number of Shares covered by each
outstanding Option and the number of Shares which have been authorized for
issuance under the Plan but as to which no Options have yet been granted or
which have been returned to the Plan upon cancellation or expiration of an
Option, as well as the price per Share covered by each such outstanding Option,
shall be proportionately adjusted for any increase or decrease in the number of
issued Shares resulting from a stock split, reverse stock split, stock dividend,
combination or reclassification of the Common Stock, or any other increase or
decrease in the number of issued Shares effected without receipt of
consideration by the Company; provided, however, that conversion of an
convertible securities of the Company shall not be deemed to have been "effected
without receipt of consideration". Except as expressly provided herein, no
issuance by the Company of shares of stock of any class, or securities
convertible into shares of stock of any class, shall affect, and no adjustment
by reason thereof shall be made with respect to, the number or price of Shares
subject to an Option.

                  (b)      Dissolution or Liquidation. In the event of the
proposed dissolution or liquidation of the Company, to the extent that an Option
has not been previously exercised, it will terminate immediately prior to the
consummation of such proposed action.

                  (c)      Merger or Asset Sale. In the event of a merger of the
Company with or into another corporation, or the sale of substantially all of
the assets of the Company, each outstanding Option shall be assumed or an
equivalent option shall be substituted by the successor corporation or a Parent
or Subsidiary of the successor corporation. In the event that the successor
corporation does not agree to assume the Option or to substitute an equivalent
option, each outstanding Option shall become fully vested and exercisable,
including as to Shares as to which it would not otherwise be exercisable, unless
the Board, in its discretion, determines otherwise. If an Optionee whose
outstanding options have been assumed or substituted pursuant to a merger or
asset sale is removed from the Board without cause within six months of such
merger or asset sale, such removed director's outstanding options shall
immediately become fully vested and exercisable. If an Option becomes fully
vested and exercisable in the event of a merger or sale of assets, the Board
shall notify the Optionee that the Option shall be fully exercisable for a
period of thirty (30) days from the date of such notice, and the Option will
terminate upon the expiration of such period. For the purposes of this
paragraph, the Option shall be considered assumed if, following the merger or
sale of assets, the option or right confers the right to purchase, for each
Share of Optioned Stock subject to the Option immediately prior to the merger or
sale of assets, the consideration (whether stock, cash, or other securities or
property) received in the merger or

                                       6
<PAGE>

sale of assets by holders of Common Stock for each Share held on the effective
date of the transaction (and if holders were offered a choice of consideration,
the type of consideration chosen by the holders of a majority of the outstanding
Shares).

         11.      Amendment and Termination of the Plan.

                  (a) Amendment and Termination. Except as set forth in Section
4, the Board may at any time amend, alter, suspend, or discontinue the Plan, but
no amendment, alteration, suspension, or discontinuation shall be made which
would impair the rights of any Optionee under any grant theretofore made,
without his or her consent. In addition, to the extent necessary and desirable
to comply with Rule 16b-3 under the Exchange Act (or any other applicable law or
regulation), the Company shall obtain shareholder approval of any Plan amendment
in such a manner and to such a degree as required.

                  (b)      Effect of Amendment or Termination. Any such
amendment or termination of the Plan shall not affect Options already granted
and such Options shall remain in full force and effect as if this Plan had not
been amended or terminated.

         12.      Time of Granting Options.

         The date of grant of an Option shall, for all purposes, be the date
determined in accordance with Section 4 hereof. Notice of the determination
shall be given to each Outside Director to whom an Option is so granted within a
reasonable time after the date of such grant.

         13.      Conditions Upon Issuance of Shares.

         Shares shall not be issued pursuant to the exercise of an Option unless
the exercise of such Option and the issuance and delivery of such Shares
pursuant thereto shall comply with all relevant provisions of law, including,
without limitation, the Securities Act of 1933, as amended, the Exchange Act,
the rules and regulations promulgated thereunder, state securities laws, and the
requirements of any stock exchange upon which the Shares may then be listed, and
shall be further subject to the approval of counsel for the Company with respect
to such compliance.

         As a condition to the exercise of an Option, the Company may require
the person exercising such Option to represent and warrant at the time of any
such exercise that the Shares are being purchased only for investment and
without any present intention to sell or distribute such Shares, if, in the
opinion of counsel for the Company, such a representation is required by any of
the aforementioned relevant provisions of law.

         Inability of the Company to obtain authority from any regulatory body
having jurisdiction, which authority is deemed by the Company's counsel to be
necessary to the lawful issuance and sale of any Shares hereunder, shall relieve
the Company of any liability in respect of the failure to issue or sell such
Shares as to which such requisite authority shall not have been obtained.

         14.      Reservation of Shares.

                                       7
<PAGE>

         The Company, during the term of this Plan, will at all times reserve
and keep available such number of Shares as shall be sufficient to satisfy the
requirements of the Plan.

         15.      Option Agreement.

         Options shall be evidenced by written option agreements in such form as
the Board shall approve.

         16.      Shareholder Approval.

         Continuance of the Plan shall be subject to approval by the
shareholders of the Company at or prior to the first annual meeting of
shareholders held subsequent to the granting of an Option hereunder. Such
shareholder approval shall be obtained in the degree and manner required under
applicable state and federal law.

                                       8<PAGE>

                                                                  Exhibit 10.69

                             DISTRIBUTION AGREEMENT

         THIS AGREEMENT is made this 1st day of May, 2000, by and between
Calypte Biomedical Corporation ("Calypte"), incorporated under the laws of
Delaware, and American Edge Medical ("DISTRIBUTOR"), incorporated under the
laws of Florida.

WHEREAS, Calypte is a developer and manufacturer of in vitro diagnostic kits
and kit components, and whereas DISTRIBUTOR wishes to commercially distribute
said kits and kit components in its Territory;

WHEREAS, in consideration of the mutual covenants and promises set forth
below, and with intent to be legally bound, the parties agree as follows:

ARTICLE 1 - DEFINITIONS
         (A) "Product" shall mean the products listed in Schedule 1 hereof.

         (B) "Territory" shall mean South Africa.

         (C) "Exclusive Distributor" shall mean that no other distributor,
             regardless of location of principal offices shall have any rights
             to commercially distribute the Products for sale in the Territory.

         (D) "Trademarks" shall mean those commercial marks listed in Schedule
             4 hereof.

ARTICLE 2 - APPOINTMENT OF DISTRIBUTOR
2.0      APPOINTMENT Calypte hereby designates and appoints DISTRIBUTOR as its
         Exclusive Distributor in the Territory for the sale, promotion,
         support, and distribution of the Products in the Territory, subject to
         the terms and conditions of this Agreement.

2.1      INDEPENDENT CONTRACTOR Except for the limited purpose set forth
         herein, nothing in this Agreement shall be deemed to constitute a
         partnership between the parties hereto or be deemed to constitute
         DISTRIBUTOR as agent or employee for Calypte for any purpose,
         including the right to contract in the name of or for the account of
         Calypte nor to assume or create any liability or obligation of any
         kind, express or implied, on behalf of Calypte in any way or for any
         purpose. This Agreement does not constitute a Trademark license or
         grant of Trademark rights. The relationship between the parties is
         that of independent contractors in which Calypte is the vendor and
         DISTRIBUTOR is the vendee.

ARTICLE 3 - TERM
3.0      EFFECTIVE DATE This Agreement shall become effective as of the date
         first shown in this Agreement.

3.1      TERM Unless sooner terminated or unless renewed as provided herein,
         this Agreement shall terminate on April 31, 2001.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

1

<PAGE>

3.2      EXTENSION Unless sooner terminated or otherwise renewed as provided
         herein, DISTRIBUTOR shall have the right to renew this Agreement for
         additional two (2) year periods provided: i) DISTRIBUTOR meets or
         exceeds the sales minima detailed in Schedule 3, and as agreed upon
         for subsequent periods, and ii) DISTRIBUTOR notifies Calypte in
         writing of its intention to renew the Agreement no less than ninety
         (90) days prior to the date the Agreement would otherwise terminate,
         and iii) DISTRIBUTOR has not declined distribution rights for any new
         Product which Calypte has offered to DISTRIBUTOR during the term of
         the Agreement, provided the new Products offered to DISTRIBUTOR are
         Products which DISTRIBUTOR could be reasonably expected to sell.

3.3      PERFORMANCE REVIEW. On or before ninety (90) days prior to March 1 of
         each year during the term hereof and all renewals, DISTRIBUTOR shall
         have the right to a review with Calypte of its performance under this
         Agreement. Said review may take personally or by telephone between
         representatives of the parties, upon arrangements mutually agreed upon
         in advance.

ARTICLE 4   DISTRIBUTOR'S UNDERTAKINGS
         DISTRIBUTOR agrees, at its sole expense (unless otherwise expressly
         provided herein), during the term of this Agreement:

4.1.1    BEST EFFORTS At all times to use its best efforts to vigorously and
         actively market, advertise, promote, and extend the sale of the
         Products throughout the Territory. To this end, DISTRIBUTOR agrees to
         maintain an adequate and competent staff of sales and technical
         support personnel which can function in all languages of the
         Territory. All advertisements, brochures, and other materials
         distributed in connection with the sale of the Products shall be
         submitted to Calypte for prior written approval, such approval not to
         be unreasonably withheld.

4.1.2    TECHNICAL SUPPORT AND RECALL CAPABILITY To provide to Calypte's
         Technical Services department a monthly report detailing any customer
         complaint(s) related to performance of the Products, such report to be
         issued even in the absence of complaints during the reporting period.
         Complaint reports shall provide full particulars regarding the nature
         of the complaint(s) and mechanism(s) of successful resolution.
         DISTRIBUTOR also certifies that it has, and shall maintain, the
         capability of tracking Product shipments by lot number in order to
         facilitate a Product recall should such a recall be required.

4.1.3    MINIMA [*]

4.2      EXCLUSIVE TERRITORY Not to solicit customers for any of the Products
         outside the Territory, either directly or through any third party,
         without Calypte's prior written approval. Furthermore, should it
         become evident that Product sold by DISTRIBUTOR within the Territory
         is being resold outside the Territory by any customer of DISTRIBUTOR,
         to take such action as may be necessary to discontinue that practice.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

2

<PAGE>

4.3.1    REGISTRATION AND PERMITS At no charge to Calypte, to provide
         reasonable assistance to Calypte in the registration of the Products
         with the regulatory authorities in the Territory, and to provide
         reasonable assistance in securing such licenses and registrations
         which may be required in connection with the importation and sale of
         the Products in the Territory. Such assistance may include among
         others DISTRIBUTOR providing to Calypte, or directly to authorities,
         such information as may be necessary to permit the importation of
         Product or components, occasional communication with regulatory
         authorities, and the coordination of Product regulatory trials. Such
         trials may require DISTRIBUTOR to provide instrumentation, laboratory
         disposables, and the training and monitoring of trial sites. Calypte
         shall offer such guidance and test kits as may be required and
         commercially reasonable in Calypte's opinion, plus payment of trial
         site fees directly associated with local registration of the
         Products. Registration of the urine HIV-1 EIA and Western Blot must
         be successfully completed no later than August 30, 2000.

4.3.2    If permitted by prevailing law within the Territory, to register the
         Products in the name of Calypte. In the event that local law demands
         that Product registrations be held and administered by a local entity,
         then Calypte, at its option, shall appoint either DISTRIBUTOR or an
         independent party for this purpose. In any event, the party
         administering the registration shall at all times administer the
         registration(s) in accordance with Calypte's instruction.

4.3.3    To hereby certify that local law permits multiple parties, either
         consecutively or concurrently, to distribute the Products in the
         Territory, either by transfer of pre-existing registrations or through
         re-registration. Furthermore, DISTRIBUTOR hereby certifies that in
         the event that this agreement is terminated for any reason by either
         party, DISTRIBUTOR shall not obstruct or challenge in any manner
         whatsoever the prompt and orderly transfer of Product registration(s)
         to another distributor, nor shall DISTRIBUTOR obstruct or challenge
         in any manner the re-registration of the Products by another
         distributor as the case may be.

4.4.1    ROLLING DEMAND PURCHASE FORECAST On a monthly basis, and no later than
         the first Monday of the month, to provide to Calypte a six-month
         rolling purchase forecast. The first three months of the forecast
         shall constitute an irrevocable commitment to purchase. In this
         fashion, DISTRIBUTOR commits monthly to one new month of purchases
         three months in the future.

4.4.2    SALES REPORTS To submit to Calypte within thirty days of January 1 and
         July 1of each year a written summary as to the prevailing market
         conditions, the attitudes of customers, the activities of competitors,
         or any other market conditions which may significantly impact the
         sales of the Products in the Territory.

4.5.1    HANDLING OF PRODUCTS To ensure that the Products are handled, stored,
         and shipped in accordance with Calypte's instructions.

4.5.2    To order, and to maintain a representative selection of Calypte's
         up-to-date sales literature or other promotional material in good
         condition.

4.5.3    To maintain such stock of the Products as is reasonably necessary to
         enable DISTRIBUTOR to comply with its obligations hereunder.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

3

<PAGE>

4.6      SALES LEADS To exercise its best judgement to follow up on sales leads
         supplied by Calypte.

4.7      CONFIDENTIALITY Not at any time to divulge to any third party any
         Confidential Information relating to the Products or to Calypte's
         affairs or business or method of carrying on business, except so far
         as is necessary, to those authorized to have access to such
         information within DISTRIBUTOR's organization.

         DISTRIBUTOR may receive information from Calypte, its personnel, or
         through DISTRIBUTOR's activities under this Agreement, either by
         direct or indirect communication or observation; more specifically,
         Calypte will make available to DISTRIBUTOR, after execution of this
         Agreement, such marketing and quality control data, and other
         proprietary, secret, and confidential information owned by Calypte
         which, in the opinion of Calypte, are necessary for DISTRIBUTOR to
         sell the Products (herein collectively referred to as "Confidential
         Information").

         DISTRIBUTOR shall not make use of the Confidential Information other
         than in connection with the marketing and sale of the Products under
         this Agreement and shall under no circumstances disclose the
         Confidential Information to any third party. Except for such of the
         Confidential Information that becomes publicly available through
         Calypte or independent third parties, DISTRIBUTOR shall not use,
         employ or exploit the Confidential Information, except for the direct
         benefit of Calypte, without Calypte's written consent for the term of
         this Agreement and seven (7) years thereafter.

4.8      SUB-DISTRIBUTORS Not to appoint or subcontract, without the prior
         written approval of Calypte, any subdistributors or sales
         representatives in the Territory in connection with the performance of
         this Agreement. In the event that Calypte grants such approval, such
         appointment shall be made only in the name and for the account of
         DISTRIBUTOR, shall be for a term no longer than the term of this
         Agreement, and shall not confer upon such subdistributors and/or
         independent sales representatives any rights greater than those which
         are granted by Calypte to DISTRIBUTOR under this Agreement.
         DISTRIBUTOR shall also impose on any such subdistributors and/or
         independent sales representatives the same obligations that Calypte
         has imposed on DISTRIBUTOR under this Agreement for the purpose of
         protecting the goodwill of Calypte and the Products.

4.9      LEGAL STANDARDS To advise Calypte in writing of any changes which
         DISTRIBUTOR becomes aware of in legal standards within the Territory
         pertaining to the Products during the term of this Agreement,
         including but not limited to packaging, labeling and ingredient
         standards, sufficiently in advance of the imposition of such legal
         standards as to permit Calypte's orderly scheduling and delivery of
         Product within DISTRIBUTOR's requested time of shipment.

4.10.1   LABELING To ensure that the Products are sold and promoted in the form
         and with the labeling or markings designated by Calypte, and not to
         alter, remove, or interfere therewith without the prior written
         consent of Calypte.

4.10.2   DISTRIBUTOR LABELS Notwithstanding the generality of the foregoing,
         Calypte hereby authorizes DISTRIBUTOR to affix a small label which
         denotes DISTRIBUTOR as the authorized distributor in the Territory,
         such label to be applied in a manner which does not obscure Calypte's
         tradenames or other marks.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

4

<PAGE>

4.11.1   TRADEMARKS To respect Calypte's rights in connection with the Products
         (including but not limited to Calypte's patents, trademarks, and
         copyrights), to comply with all local laws and regulations with
         respect thereof, and to assist Calypte in taking any steps necessary
         to defend such rights. Any reasonable expenses incurred under this
         paragraph by DISTRIBUTOR, and which are preapproved by Calypte, shall
         be reimbursed by Calypte.

4.11.2   To acknowledge at all times Calypte's exclusive right, title, and
         interest in and to the trademarks associated with the Products listed
         in Schedule 1 and registered by Calypte in the United States of
         America or the Terrritory; and not at any time to do or cause to be
         done any act or any thing contesting or in any way impairing or
         tending to impair any part of such right, title and interest. In
         connection with any reference to the trademarks, DISTRIBUTOR shall
         not in any manner represent that it has ownership interest in the
         trademarks or registration thereof, but shall clearly indicate
         Calypte's ownership of the trademarks.

4.11.3   To use no trademarks, trade names, corporate names, or trade styles
         employing the trademarks, whether in advertising or otherwise, without
         the prior written consent of Calypte, such consent not to be
         unreasonably withheld, and generally not to produce any advertising or
         promotional material or activity without Calypte's written consent.
         Except as provided in Article 9.2, any and all use by DISTRIBUTOR of
         said trademarks, trade names, corporate names or trade styles within
         the Territory shall cease upon the expiration or termination of this
         Agreement.

 4.12    PRESS To make no statements to the press concerning Calypte's
         personnel, business practices, Product development efforts, or alleged
         Product performance problems without the prior written consent of
         Calypte.

4.13     MANAGEMENT CHANGE To provide to Calypte prompt notice, in writing, of
         any change of key management or ownership and any change in the mode
         of operation of DISTRIBUTOR.

4.14     PROOF OF SALE To expressly represent that any Products purchased are
         for the purpose of sale in the Territory and will furnish upon
         Calypte's requests, documents which certify that the Products have
         been sold in that Territory. DISTRIBUTOR further represents that it
         will undertake all appropriate steps to ensure that the Products are
         sold exclusively to customers which are permitted under the laws of
         the Territory to purchase and use the Products.

4.15     AUDIT To permit Calypte staff or a Calypte designee, upon reasonable
         advance notice, to audit DISTRIBUTOR's premises and sales records in
         connection with this Agreement at no expense to DISTRIBUTOR.

4.16     COMPETING PRODUCTS During the term of this Agreement, DISTRIBUTOR
         agrees that it shall not directly nor through any third party,
         including African Medical Solutions or any of African Medical
         Solutions' partners, collaborators, or joint venture partners
         manufacture, sell, promote, market, or advertise without prior written
         permission from Calypte, any non-Calypte in vitro diagnostic test for
         the detection of HIV antibodies.

4.17     NEW PRODUCTS To accept distribution rights and obligations for new
         Products which the parties believe DISTRIBUTOR could be reasonably
         expected to sell as they may become available from time to time, and
         under such terms and

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

5

<PAGE>

         conditions as the parties may negotiate in good faith. However this
         obligation may be imposed only for products which are reasonably
         related to the sales of existing Products by DISTRIBUTOR.

ARTICLE 5   CALYPTE'S UNDERTAKINGS

Calypte agrees, during the term of this Agreement:

5.1.1    EXCLUSIVE DISTRIBUTOR To limit the authorized sale of the Products in
         the Territory to DISTRIBUTOR, and to take such action as may be
         necessary to ensure compliance of third parties in this regard.

5.2      FILLING ORDERS To use its best efforts to fill all orders of
         DISTRIBUTOR for delivery of the Products hereunder. Orders shall be
         placed in writing and mailed or transmitted by facsimile in accordance
         with the Rolling Demand Forecasting system described in Section 4.4.1
         hereof. No order from DISTRIBUTOR shall be binding upon Calypte until
         such order is accepted by Calypte in writing by mail or facsimile,
         such acceptance not to be unreasonably withheld. Calypte shall make
         commercially reasonable efforts to fill orders which are placed in
         addition to orders placed through the Rolling Demand Forecasting
         system.

5.3      TRADEMARKS To use its best efforts to maintain the Trademarks in good
         legal standing in the Territory.

5.4      SALES MATERIAL To furnish to DISTRIBUTOR, at Calypte's expense, a
         reasonable supply of sales literature and promotional materials. The
         promotional materials may be furnished in the English language.
         DISTRIBUTOR may translate the materials at its own expense, and with
         prior approval from Calypte, such approval not to be unreasonably
         withheld. Calypte may make reasonable charges if more than a nominal
         quantity of promotional materials is supplied to DISTRIBUTOR, which
         will be agreed upon between Calypte and DISTRIBUTOR in advance.

5.5      WARRANTY To warrant the Products as set out in Article 8 below.

5.6      SALES LEADS To forward to DISTRIBUTOR sales leads and inquiries from
         customers located within the Territory.

5.7      TRAINING To provide to DISTRIBUTOR such sales, marketing, and
         technical training as may be reasonably required, at Calypte's
         facility, but not to exceed one week during each year of this
         Agreement. Costs incurred in such training excluding travel and
         accommodation, but including training materials, trainer time, and a
         reasonable amount of Product shall be borne by Calypte.

5.8      To provide telephone technical support to DISTRIBUTOR during Calypte's
         normal business hours.

5.9      NEW PRODUCTS To offer to DISTRIBUTOR the right of first refusal on new
         Products which Calypte may develop from time to time, and which the
         parties believe DISTRIBUTOR may be reasonably expected to sell.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

6

<PAGE>

5.10     NEW MARKETS To negotiate in good faith with DISTRIBUTOR the
         opportunity to expand the Territory governed by this Agreement,
         subject to Territory availability.

ARTICLE 6   PRICE AND PAYMENT

6.1      [*]

6.2      [*]

6.3      CURRENCY Payment shall be made in U.S. dollars.

ARTICLE 7   SHIPPING-TITLE AND RISK-CANCELLATION

7.1      [*]

7.2      [*]

ARTICLE 8   WARRANTY - NO CONSEQUENTIAL DAMAGES - INDEMNITY

8.1      WARRANTY Calypte warrants the Products to be of sufficient quality of
         materials and manufacture as to meet the claims and specifications set
         forth in the Product's packaging and labeling when used according to
         the directions provided therein.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

7

<PAGE>

         EXCEPT AS OTHERWISE EXPRESSLY PROVIDED HEREIN, CALYPTE MAKES NO
         REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING
         FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER MATTER, WITH RESPECT TO
         THE PRODUCTS. DISTRIBUTOR's exclusive remedy will be for direct
         damages, and Calypte's total liability for any and all losses and
         damages arising out of any cause whatsoever (whether such cause be
         based in contract, warranty, negligence, strict liability, other tort
         or otherwise) will in no event exceed DISTRIBUTOR's landed cost of the
         Products in respect to which such cause arises or, at Calypte's
         option, the replacement of such Products. In no event will Calypte be
         liable for incidental, consequential or punitive damages resulting
         from any cause whatsoever. Calypte warrants that at the time that the
         Products left Calypte's possession, they were deemed to be of good
         quality.

8.2      DEFECTS Without limiting the generality of the foregoing, CALYPTE
         SHALL NOT BE BOUND TO MAKE GOOD ANY DEFECT IN THE PRODUCTS WHERE THE
         PRODUCTS HAVE BEEN SUBJECTED TO MISUSE, NEGLECT, OR ACCIDENTAL
         DAMAGE, UNLESS SUCH DEFECT RESULTED FROM THE NEGLIGENCE OF CALYPTE.

8.3      TRADEMARKS Calypte is the record owner of registrations for its
         trademarks in the Territory and believes it has the right to use these
         trademarks throughout the Territory. Notwithstanding, CALYPTE MAKES NO
         EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE PRODUCTS WILL
         NOT INFRINGE THE LEGITIMATE AND VALID TRADEMARKS, TRADE NAMES, OR
         OTHER INDUSTRIAL PROPERTY RIGHTS OF THIRD PARTIES IN THE TERRITORY.
         DISTRIBUTOR shall immediately notify Calypte of any such claims of
         others, and Calypte shall, at its sole option, have the right to
         assume the defense of any such claim.

8.4      INSPECTION It shall be the responsibility of DISTRIBUTOR to inspect
         the Products after taking title to same. Notwithstanding Article 8.1
         above, Calypte shall not be liable for any shortage, breakage, or
         damage to the Products or for any breach of warranty, implied or
         otherwise, unless it receives written notice of any defect or
         shortcoming within ten (10) days after the date on which DISTRIBUTOR
         takes title to the Products, and the defect or shortcoming results
         from the fault or negligence of Calypte.

8.5      INDEMNIFICATION Calypte shall indemnify and hold DISTRIBUTOR harmless
         from any claims, demands, liabilities, suits or expenses of any kind
         arising out of any misrepresentations which Calypte makes concerning
         the Product supplied by Calypte.

         Calypte shall indemnify DISTRIBUTOR for any damages or loss actually
         paid by DISTRIBUTOR resulting from a legal decision on a claim by
         third parties made against DISTRIBUTOR and which is caused by Calypte
         with respect to products made or supplied by Calypte.

         DISTRIBUTOR is responsible for, and shall hold Calypte harmless from
         any loss, claim, damage, illness or injury to persons or property
         which arises out of or pertains to the sale, use, packaging,
         advertising, or promotion of the Product, and which is caused by
         DISTRIBUTOR or DISTRIBUTOR's subdistributors, agents or employees.
         This provision shall survive the expiration or termonation of this
         Agreement for any reason and shall be liberally construed in favor of
         Calypte.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

8

<PAGE>

ARTICLE 9   TERM AND TERMINATION

9.1.1    TERMINATION FOR CAUSE Calypte, at its sole option, may immediately
         terminate this Agreement with respect to the Territory, upon giving
         notice to this effect, whenever any of the following events occurs:

         (i) if any governmental unit within the Territory threatens (in the
         sole judgement of Calypte) to enact or enacts any law, decree or
         regulation which would restrict the right of Calypte to terminate or
         elect not to renew this Agreement as herein provided, or would make
         Calypte liable to DISTRIBUTOR for compensation or damages upon
         termination or failure to renew this Agreement;

         (ii) if DISTRIBUTOR at any time discontinues or abolishes its
         business, files a petition of bankruptcy or insolvency or admits in
         writing its inability to pay its debts as they become due and
         payable, or if DISTRIBUTOR is adjudicated bankrupt or insolvent, or
         if there is filed any petition seeking reorganization of DISTRIBUTOR,
         or if a receiver is appointed for all or substantially all of
         DISTRIBUTOR's property, or if DISTRIBUTOR makes an assignment for the
         benefit of creditors or if any proceedings are instituted for the
         liquidation or winding up of DISTRIBUTOR;

         (iii) if DISTRIBUTOR uses Calypte's trademarks or trade names or
         styles in any way which might deceive or mislead the consumer or
         which might in any way damage or impair the reputation or value of
         such trademarks, trade names, or styles;

         (iv) if DISTRIBUTOR fails to comply with any of the terms or
         conditions herein contained and, after notice by Calypte requiring
         DISTRIBUTOR to make good such default, DISTRIBUTOR fails to cure such
         default within sixty (60) days after receipt of such notice;

         (v) if DISTRIBUTOR is at any time nationalized or falls under the
         control of any governmental unit within the Territory;

         (vi) if DISTRIBUTOR's authority to carry on business is cancelled by
         competent authorities;

         (vii) if control of DISTRIBUTOR should be transferred to another
         party, whether such party is a competitor of Calypte or otherwise; or

         (viii) all Products are deleted from Schedule 1.

         (ix) Clause 15.1 herein is breached

         (x) HIV-1 Urine EIA and HIV-1 Urine Western Blot have not been
         registered on or before August 30, 2000.

9.1.2    DISTRIBUTOR, at its sole option, may immediately terminate this
         Agreement with respect to the Territory, upon giving notice to this
         effect, whenever any of the following events occurs:

         (i) if Calypte at any time discontinues or abolishes its business,
         files a petition of bankruptcy or insolvency or admits in writing its
         inability to pay its debts as they

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

9

<PAGE>

         become due and payable, or if Calypte is adjudicated bankrupt or
         insolvent, or if there is filed any petition seeking reorganization
         of Calypte, or if a receiver is appointed for all or substantially
         all of Calypte's property, or if Calypte makes an assignment for the
         benefit of creditors or if any proceedings are instituted for the
         liquidation or winding up of Calypte; or

         (ii) if Calypte fails to comply with any of the terms or conditions
         herein contained and, after notice by DISTRIBUTOR requiring Calypte to
         make good such default, Calypte fails to cure such default within
         sixty (60) days after receipt of such notice.

9.2.1    Upon termination or expiration of this Agreement for any reason:

         i) at Calypte's option, DISTRIBUTOR may sell its remaining inventory
         of Product within the Territory, or shall make available to Calypte or
         Calypte's designee, all current stocks of Product held by DISTRIBUTOR
         with a minimum of four (4) months' expiration remaining, at
         DISTRIBUTOR's landed cost, FOB DISTRIBUTOR's warehouse, which shall
         include any duty, freight, insurance documentation and inland freight
         to warehouse distribution.

         ii) DISTRIBUTOR shall at its own expense return to Calypte or its
         designee all Confidential Information furnished by Calypte in
         accordance with Article 5.2 hereof, as well as all sales literature,
         catalogues, samples, and other promotional materials supplied by
         Calypte;

         iii) Calypte will not be liable to pay to DISTRIBUTOR any termination
         compensation, benefits or damages of any kind whatsoever, whether for
         DISTRIBUTOR's loss of present or prospective profits, anticipated
         sales, expenditures, investments or commitments made in connection
         with this Agreement, or due to the termination of any of DISTRIBUTOR's
         employees, agents, or subdistributors, or due to any other matter or
         cause whatsoever, and whether provided by any current or future law,
         regulation or interpretation thereof by any authority exercising
         jurisdiction over this Agreement, and;

         iv) all obligations of Calypte shall be canceled, but such expiration
         or termination will not affect any of Calypte's rights hereunder, and
         Calypte will further have the right, immediately upon such expiration
         or termination, to appoint a new distributor or sales representative.
         Such expiration or termination will not affect DISTRIBUTOR's
         obligation to make payment for any orders of the Products which remain
         unpaid at such time.

ARTICLE 10  ASSIGNMENT

         DISTRIBUTOR shall not be entitled to assign its rights and obligations
         under this Agreement without the prior written consent of Calypte. In
         the context of this Agreement, a change in control or ownership of the
         DISTRIBUTOR, whether involving a competitor of Calypte or otherwise,
         shall constitute assignment, and in accordance with 9.1.1(vii) Calypte
         may, at its discretion, terminate this Agreement.

ARTICLE 11  WAIVER The failure of either party to assert a right under, or to
         enforce at any time or for any period of time, the provisions hereof
         or the failure of either party to exercise an option herein shall not
         be construed as a waiver of

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

10

<PAGE>

         such provision or option and shall in no way affect that party's
         right to enforce such provisions or exercise such options. A waiver
         of any breach of any provision of this agreement shall not be
         construed as a continuing waiver of other breaches of the same or
         other provisions of this agreement.

ARTICLE 12  ENTIRE AGREEMENT

         With the exception of previously signed Confidentiality Agreements,
         this Agreement cancels and supersedes any previous understandings or
         agreements, oral or written, between the parties relating to the
         subject matter hereof, including any previously existing
         distributorship arrangement. This Agreement expresses the complete and
         final understanding of the parties with respect to the subject matter
         hereof, and may not be changed in any way except upon the explicit
         intention of both parties expressed by a signed written agreement. Any
         terms or conditions stated in DISTRIBUTOR's purchase orders
         inconsistent with this Agreement shall be null and void.

ARTICLE 13  SEVERABILITY

         If any provision of this Agreement shall be found by a court of
         competent jurisdiction to be invalid or unenforceable, the invalidity
         or unenforceability of such provision shall not affect the other
         provisions of this Agreement and all provisions not affected by such
         invalidity shall remain in full force and effect but that in any
         event, the provisions concerning payment for the Product shall be
         binding upon the parties.

ARTICLE 14  NOTICES

14.1     NOTICE Any notice required or permitted by this Agreement shall be in
         writing and in the English language, and shall be delivered personally
         or by registered air mail, postage prepaid, or by facsimile, addressed
         to the parties as follows:

If to Calypte:                      Calypte Biomedical Corporation
                                    1265 Harbor Bay Parkway
                                    Alameda, California  94502
                                    United States of America

                                    Facsimile: 510-814-8408

                                    Attention: President

If to DISTRIBUTOR:                  American Edge Medical
                                    425 24th Street
                                    West Palm Beach, FL  33407

                                    Facsimile: 561-655-3494

                                    Attention: President

14.2     RECEIPT Any notice sent by registered prepaid air mail properly
         addressed and posted shall be deemed to have been received ten (10)
         days after it is delivered to the postal authorities in the country of
         the party by whom it is sent. If sent by

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

11

<PAGE>

         facsimile, a copy of the facsimile shall be sent promptly by
         registered prepaid air mail to the addressee.

14.3     VERBAL NOTICE Nothing contained herein shall justify or excuse
         failure to give verbal notice for the purpose of informing the other
         party thereof when prompt notification is appropriate, but such verbal
         notice shall not satisfy the requirement of written notice.

ARTICLE 15  APPLICABLE LAWS

15.1     EXPORT LAWS Calypte is subject to U.S. laws and regulations governing
         the export of U.S. products. DISTRIBUTOR agrees that it will not
         directly or indirectly engage in any acts which would cause Calypte to
         be found in violation of such laws or regulations.

15.2     PAYMENTS DISTRIBUTOR acknowledges that certain laws of the United
         States may result in the imposition of sanctions on Calypte and its
         employees in the event that offers, promises, or payments are directly
         or indirectly made to government officials or others for the purpose
         of influencing decisions favorable to Calypte, and, therefore
         DISTRIBUTOR agrees that neither it nor its employees will commit such
         acts or engage in such activities and that DISTRIBUTOR shall defend,
         indemnify, and hold Calypte harmless for any damages, claims,
         liabilities and expenses which arise or allegedly arise from
         DISTRIBUTOR's violation of the obligations of articles 15.1 or 15.2.

15.3     ASSURANCES DISTRIBUTOR agrees to furnish to Calypte, by affidavit or
         other reasonable means from time to time at Calypte's request, and to
         the reasonable satisfaction of Calypte, assurances that the
         appointment of DISTRIBUTOR hereunder, its activities under this
         Agreement, and the payment to DISTRIBUTOR of any monies or
         consideration contemplated hereunder are proper and lawful under the
         laws in force in the Territory. DISTRIBUTOR further represents that
         no person employed by it is an official of any government agency or a
         corporation owned by a government unit within the Territory and that
         no part of any monies or consideration paid hereunder shall accrue
         for the benefit of any such official.

15.4     TERRITORY LAWS If Calypte determines that the appointment or use of
         DISTRIBUTOR is not permitted under the laws and regulations in force
         in the Territory, Calypte has the right, at its sole discretion and
         upon notice to DISTRIBUTOR, to terminate this Agreement as Calypte
         sees fit. Upon notice of this decision, DISTRIBUTOR will cease its
         activities under this Agreement and shall not seek damages or
         compensation in any form, according to Article 9 of this Agreement.

ARTICLE 16  GOVERNING LAW
         This Agreement and the obligations of the parties hereunder shall be
         governed and construed in accordance with the laws of the State of
         California, U.S.A.

ARTICLE 17  FORCE MAJEURE
         Calypte and DISTRIBUTOR will be excused from failure to perform under
         this Agreement and will not be liable in any way for any loss if such
         failure is due to causes beyond the reasonable control of either
         party, including but not limited to, natural disasters such as
         earthquakes or floods, fires, riots, strikes and other labor

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

12

<PAGE>

         disputes, war conditions, shortage of raw materials or government
         action for the period any such conditions exist.

ARTICLE 18  HEADINGS
         The headings used herein are for convenience only and in no way affect
         the liabilities, obligations, or responsibilities of the parties
         hereto.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement.

CALYPTE BIOMEDICAL CORPORATION

By: /s/ Nancy E. Katz
   --------------------------

Title: President, COO, CFO
      -----------------------

Date: 4/24/00
     ------------------------

AMERICAN EDGE MEDICAL

By: /s/ Oscar Kizar
   --------------------------

Title: Marketing Director
      -----------------------

Date: 04/24/00
     ------------------------

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

13

<PAGE>

                              SCHEDULE 1 - PRODUCTS

Calypte HIV-1 Urine EIA Test Kit  An enzyme immunoassay in microwell format
for the detection of antibodies to HIV-1 in urine.

                        Cat. No. 700000          480 tests
                        Cat. No. 700001          192 tests

Cambridge Biotech HIV-1 Serum Western Blot Test Kit.  A Western Blot
supplemental immunoassay for the analysis of serum or plasma samples that are
repeatedly reactive on a serum or plasma HIV-1 EIA. Cat. No. 98002    27 tests

Cambridge Biotech HIV-1 Urine Western Blot Test Kit.  A Western Blot
supplemental immunoassay for the analysis of urine samples that are
repeatedly reactive on the Calypte HIV-1 Urine EIA. Cat. No. 98076    27 tests

Cambridge Biotech HTLV I/II Serum Western Blot Test Kit.  A Western Blot
supplemental immunoassay for the analysis of serum or plasma samples that are
repeatedly reactive on a serum or plasma HTLV EIA.  Cat. No. 98051    27 tests

                               SCHEDULE 2 - PRICE

[*]

                               SCHEDULE 3 - MINIMA

[*]

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

14

<PAGE>

                             SCHEDULE 4 - TRADEMARKS

Calypte name and corporate logo
Calypte hummingbird logo
Sentinel  tradename
Cambridge Biotech name and corporate logo

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]